Crimean-Congo hemorrhagic fever-induced liver injury: a systematic review and meta-analysis

Sawai Singh Rathore¹, Ade Harrison Manju², Qingqing Wen³, Manush Sondhi⁴, Reshma Pydi⁵, Iskander Haddad⁶, Jamal Hasan⁷, Muhammad Adnan Ali⁸, Sohaib Tousif⁹, Romil Singh¹⁰, Abdul-Azeez Muhammed¹¹, Noman Khurshid Ahmed¹², and Deep Manojkumar Patel¹³

¹Dr Sampurnanand Medical College
²Faculty of Biochemical Science, University of Yaounde I
³University of California Los Angeles, Fielding School of Public Health,
⁴Kasturba Medical College Manipal
⁵Andhra Medical College
⁶Lebanese American University
⁷Al Rafidian private hospital
⁸Jinnah Sindh Medical University
⁹Ziauddin Medical University
¹⁰Mayo Clinic Rochester
¹¹Federal medical center
¹²Dow Medical College
¹³Our Lady of Fatima University College of Medicine

April 28, 2021

Abstract

Background: Crimean-Congo hemorrhagic fever (CCHF) is a fatal acute tick-borne viral infection and a substantial emerging global public health threat. This illness has a high case fatality rate of up to 40%. The liver is one of the important target organs of the CCHF virus. Objective: The aim of this meta-analysis to evaluate the correlation between CCHF and liver injury and draw more generalized inferences about the abnormal serum markers of liver injury such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) in CCHF patients. Methods: A literature search was accomplished for published eligible articles with MEDLINE/PubMed and Embase databases. All eligible observational studies and case series were included from around the world. The inclusion criteria were articles describing liver injury biomarkers AST and ALT amongst patients diagnosed with CCHF. Results: Data from 18 studies, consisting of 1238 patients with CCHF were included in this meta-analysis. The overall pooled prevalence of at least one raised liver injury biomarker was 77.95% (95% CI, I2 = 88.50%, p < 0.0001). Similarly, pooled prevalence of elevated AST and ALT was 85.92% (95% CI, I2 = 85.27%, p < 0.0001) and 64.30% (95% CI, I2 = 88.32%, p < 0.0001) respectively. Both Egger and Begg-Mazumdar's tests detected no apparent publication bias in all three meta-analyses(p > 0.05). Conclusion: These elevated liver injury biomarkers have been identified as significant prognostic factors. Hence, Physicians must recognize and continuously monitor these biomarkers, since these aid early stratification of prognosis and the prevention of severe outcomes in infection with such a high case fatality rate.

Hosted file

_CCHF New (1).pdf available at https://authorea.com/users/393104/articles/519968-crimean-









